ProCURE fosters forefront cancer research at the same time that encourages innovation and technology transfer. We believe are particularly proud of having been the incubator for the launching of 3 spin-off companies, VCNBiosciences, Xenopat and Metabostem, all founded by threee of our group leaders.
VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.
To learn more anout VCN Biosciences technologies click here
Advanced Preclinical Services
Xenopat offers researchers and companies devoted to the development of new anticancer drugs, the most innovative tools available. Xenopat offers researchers the OrthoXenoBank®, which is composed of several orthotopic models of different tumor types (orthoxenografts®), characterized at histological and genetic levels, with different sensitivity to diverse chemotherapies.
Personalized Cancer TreatmentXenopat offers healthcare professionals and patients the most advanced technology in order to select the best treatment in the fight against cancer. Xenopat offers the possibility to generate an orthoxenograft® from a small fragment of the patient’s tumor. This mouse model allows us to test several drugs and find the best therapy for each patient.
METABOSTEM is a Barcelona-based Biopharmaceutical Company passionately committed to transforming the lives of cancer patients by entering a new dimension of precision medicine. The pioneering science behind METABOSTEM has the goal of developing breakthrough oncology drugs directed to the unique metabolic features of cancer stem cells (CSCs), the most dangerous & deadliest type of cancer cell. The Company is a spinout of the Catalan Institute of Oncology.